1000mg of (Hesperidin and Diosmin mixture) three times daily for 7 days 1000mg of (Hesperidin and Diosmin mixture) two times daily for 3 days

standard care therapy in quarantine hospitals

Coronavirus Infection

Hesperidin and Diosmin mixture

Hesperidin and Diosmin for Treatment of COVID-19

Randomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in Egypt

Prof. Dr. Kamal Mohammed Okasha

Professor

Tanta University

Randomized double-blind controlled Parallel study

Nafamostat mesylate on top of best standard of care.

COVID19

administered intravenously as a continuous infusion

Nafamostat Mesilate

Placebo

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)

Time-to-clinical improvement (time from randomization to an improvement of two points (from the status at randomization) on a 7 category ordinal scale or live discharge from the hospital, whichever came first.

Rate of patients showing improvement of 2 points in 7 category ordinal scale (with 7 points the worst)(PubMed ID: 32187464)

Proportion of patients who will progress to critical illness/death

Change Sequential organ failure assessment score (SOFA score) over time. The Score ranges from 0 to 24 (with 24 the worst)(PubMed ID: 11594901)

Duration of hospitalization in survivors (days)

Number of patients who require ventilation

Proportion of patients who develop arrhythmia, or myocardial infarction, or other cardiovascular disease not present at the baseline

Gian Paolo Rossi, MD, FAHA, FACC

Prof.

University Hospital Padova

Yokohama City University

University of Zurich

Randomized, double blind, placebo-controlled parallel-group trial, on top of best standard of care

Randomization will be done with an algorithm tailored to the study design. Investigators and patients will be blinded to the treatment administered.

Patients who begin cART in regular clinical routine with 2N(t)RTI plus raltegravir (n=10 patients) will be offered to participate in this observation arm, but only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.

Patients who begin cART in regular clinical routine with 2N(t)RTI plus either a boosted protease inhibitor or efavirenz (n=10 patients) at standard doses will be offered to participate in this observation arm. They will be offered to participate in this trial only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.

HIV-1

Johann Wolfgang Goethe-University Hospital

Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation

Comparing the Dynamics of Different HIV-1 cDNA Species in CD4-positive T-cells and HIV-1 RNA in Plasma of Infected Individuals After Initiation of Antiretroviral Therapy With or Without Raltegravir

superinfection/protease

Hesperidin and Diosmin for Treatment of COVID-19

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation

The most complete medicinal herbs database backed by science